Q4 2024 EPS Estimates for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Lifted by Analyst

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) – Equities researchers at Leerink Partnrs lifted their Q4 2024 earnings per share (EPS) estimates for shares of Aurinia Pharmaceuticals in a research report issued to clients and investors on Thursday, May 2nd. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will earn $0.12 per share for the quarter, up from their prior forecast of $0.09. The consensus estimate for Aurinia Pharmaceuticals’ current full-year earnings is ($0.06) per share. Leerink Partnrs also issued estimates for Aurinia Pharmaceuticals’ FY2025 earnings at $0.23 EPS.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Thursday, February 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). The business had revenue of $45.10 million for the quarter, compared to the consensus estimate of $45.00 million. Aurinia Pharmaceuticals had a negative net margin of 32.69% and a negative return on equity of 15.06%. Aurinia Pharmaceuticals’s revenue was up 58.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.18) EPS.

Several other equities analysts have also recently issued reports on the stock. Cantor Fitzgerald reduced their price target on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. StockNews.com raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Aurinia Pharmaceuticals in a research report on Friday, March 1st. Royal Bank of Canada decreased their price objective on Aurinia Pharmaceuticals from $13.00 to $8.00 and set an “outperform” rating for the company in a report on Friday, February 16th. Finally, Jefferies Financial Group dropped their target price on shares of Aurinia Pharmaceuticals from $9.50 to $9.00 and set a “hold” rating on the stock in a report on Friday, February 16th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Aurinia Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Stock Down 0.8 %

Shares of NASDAQ AUPH opened at $5.12 on Monday. The firm has a fifty day simple moving average of $5.16 and a two-hundred day simple moving average of $7.06. Aurinia Pharmaceuticals has a 12 month low of $4.71 and a 12 month high of $12.43. The company has a current ratio of 5.60, a quick ratio of 5.05 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $732.26 million, a PE ratio of -11.91 and a beta of 1.36.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several large investors have recently modified their holdings of AUPH. China Universal Asset Management Co. Ltd. grew its position in Aurinia Pharmaceuticals by 95.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,673 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,798 shares during the last quarter. Compagnie Lombard Odier SCmA grew its holdings in shares of Aurinia Pharmaceuticals by 8.7% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 25,000 shares of the biotechnology company’s stock valued at $225,000 after buying an additional 2,000 shares during the last quarter. Nordea Investment Management AB increased its position in shares of Aurinia Pharmaceuticals by 1.0% during the third quarter. Nordea Investment Management AB now owns 214,500 shares of the biotechnology company’s stock valued at $1,687,000 after acquiring an additional 2,100 shares in the last quarter. HighMark Wealth Management LLC raised its holdings in Aurinia Pharmaceuticals by 3.0% in the 1st quarter. HighMark Wealth Management LLC now owns 75,196 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 2,197 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Aurinia Pharmaceuticals by 9.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,634 shares of the biotechnology company’s stock valued at $257,000 after acquiring an additional 2,390 shares in the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.